These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23929729)

  • 1. Pilot study assessing a seven-day continuous intrathecal topotecan infusion for recurrent or progressive leptomeningeal metastatic cancer.
    Tran HC; Gardner S; Weiner HL; Liebes LF; Finlay JL
    J Oncol Pharm Pract; 2014 Jun; 20(3):229-32. PubMed ID: 23929729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor.
    Stewart CF; Iacono LC; Chintagumpala M; Kellie SJ; Ashley D; Zamboni WC; Kirstein MN; Fouladi M; Seele LG; Wallace D; Houghton PJ; Gajjar A
    J Clin Oncol; 2004 Aug; 22(16):3357-65. PubMed ID: 15310781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
    Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
    Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination.
    Slavc I; Schuller E; Czech T; Hainfellner JA; Seidl R; Dieckmann K
    J Neurooncol; 1998; 38(2-3):213-8. PubMed ID: 9696374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.
    Frangoul H; Ames MM; Mosher RB; Reid JM; Krailo MD; Seibel NL; Shaw DW; Steinherz PG; Whitlock JA; Holcenberg JS
    Clin Cancer Res; 1999 Dec; 5(12):3956-62. PubMed ID: 10632325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal chemotherapy delivered by a lumbar-thecal catheter in metastatic medulloblastoma: a case illustration.
    Clayton J; Vloeberghs M; Jaspan T; Walker D; MacArthur D; Grundy R
    Acta Neurochir (Wien); 2008 Jul; 150(7):709-12. PubMed ID: 18401539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrathecal topotecan in adult patients with neoplastic meningitis.
    Gammon DC; Bhatt MS; Tran L; Van Horn A; Benvenuti M; Glantz MJ
    Am J Health Syst Pharm; 2006 Nov; 63(21):2083-6. PubMed ID: 17057045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure.
    Sirachainan N; Visudtibhan A; Tuntiyatorn L; Pakakasama S; Chuansumrit A; Hongeng S
    Pediatr Blood Cancer; 2008 Jan; 50(1):169-72. PubMed ID: 16572404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
    Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
    Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topotecan as a continuous infusion over 14 days in recurrent ovarian cancer patients.
    Denschlag D; Watermann D; Hörig K; Kissel C; Tempfer C; Gitsch G
    Anticancer Res; 2004; 24(2C):1267-9. PubMed ID: 15154658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors.
    Morgan RJ; Synold T; Mamelak A; Lim D; Al-Kadhimi Z; Twardowski P; Leong L; Chow W; Margolin K; Shibata S; Somlo G; Yen Y; Frankel P; Doroshow JH
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):927-33. PubMed ID: 20107803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
    Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
    Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous and bolus intraventricular topotecan prolong survival in a mouse model of leptomeningeal medulloblastoma.
    Shackleford GM; Mahdi MY; Moats RA; Hawes D; Tran HC; Finlay JL; Hoang TQ; Meng EF; Erdreich-Epstein A
    PLoS One; 2019; 14(1):e0206394. PubMed ID: 30608927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma.
    Zamboni WC; Gajjar AJ; Mandrell TD; Einhaus SL; Danks MK; Rogers WP; Heideman RL; Houghton PJ; Stewart CF
    Clin Cancer Res; 1998 Oct; 4(10):2537-44. PubMed ID: 9796988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.
    Zamboni WC; Gajjar AJ; Heideman RL; Beijnen JH; Rosing H; Houghton PJ; Stewart CF
    Clin Cancer Res; 1998 Mar; 4(3):783-9. PubMed ID: 9533548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ventriculolumbar perfusion of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosou rea hydrochloride.
    Kochi M; Kuratsu J; Mihara Y; Takaki S; Seto H; Uemura S; Ushio Y
    Neurosurgery; 1993 Nov; 33(5):817-23. PubMed ID: 8264878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
    Rose PG; Gordon NH; Fusco N; Fluellen L; Rodriguez M; Ingalls ST; Hoppel CL
    Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962).
    Potter SL; Berg S; Ingle AM; Krailo M; Adamson PC; Blaney SM
    Pediatr Blood Cancer; 2012 Mar; 58(3):362-5. PubMed ID: 21910214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent encephaloclastic cyst induced by intraventricular topotecan.
    Mella DB; Kamiya-Matsuoka C; Liao B; Tummala S; de Groot J
    J Neurol Sci; 2015 Feb; 349(1-2):52-3. PubMed ID: 25598491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrathecal chemotherapy for leptomeningeal dissemination of medulloblastoma.
    Edwards MS; Levin VA; Seager ML; Wilson CB
    Childs Brain; 1981; 8(6):444-51. PubMed ID: 6796342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.